The Dark Side of Immuno-Oncology

ElyssaMed® is a spin-off of Gustave Roussy and INSERM. This biotech company is developing the first active cancer immunotherapy based on a cocktail of antigenic peptides (epitopes) derived from the ppCT tumor antigen delivered with an already marketed vaccine adjuvant for clinical use in non-small-cell lung cancer and neuroendocrine tumors. This innovative product, once administered to lung cancer patients, will amplify their specific immune response toward tumor cells expressing the ppCT antigen and lead to the destruction of even immune-escaped cancer cell variants.

R&D

Innovative nature of the technology 

This immunotherapy is based on the discovery by the founding team's members of the tumor antigen ppCT (Preprocalcitonin), a precursor of the hormone calcitonin (CT).
They demonstrated that ppCT, which is expressed or over-expressed in several human lung tumor types, is capable of inducing a specific immune response in most lung cancer patients and constitutes a promising target for cancer immunotherapy.

More on R&D page...

Pipeline / Products

ElyssaMed® develops multiple drug candidates targeting cancer based on a novel technological platform; its lead product EM-03 is developed to treat non-small cell lung cancer.

  • 1st in class
  • Combination of selected proprietary immunogenic peptides targeting a specific lung tumor-associated antigen.
  • MOA: this antigen overcomes tumor evasion from CD8 T-cell immunity by using a novel processing mechanism independent from TAP/Proteasome pathway
  • Route of administration: Intra-dermal injection
  • Injected with a marketed cancer vaccine adjuvant
  • API & DP produced by CMO FDA / EMA approved

More an Pipeline page …

Team

Over the past several years, the founder of ElyssaMed has directed her work toward a translational research for developing a cancer immunotherapy to treat patients suffering from lung cancer. Testing her discovery as a medical product in clinical trials is one of her personal goal as a basic researcher.

More an Team page …

Contact

You can contact us on rhe contact pages ...